NYSE:AZN - AstraZeneca Stock Price, Price Target & More

AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

AstraZeneca declared a semiannual dividend on Monday, February 5th. Stockholders of record on Friday, February 16th will be given a dividend of $0.95 per share on Monday, March 19th. This represents a dividend yield of 5.62%. The ex-dividend date of this dividend is Thursday, February 15th. View AstraZeneca's Dividend History.

AstraZeneca shares split before market open on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly issued shares were distributed to shareholders after the market closes on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.

AstraZeneca plc (NYSE:AZN) posted its quarterly earnings data on Friday, May, 18th. The company reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.20. The business had revenue of $5.18 billion for the quarter, compared to analysts' expectations of $5.24 billion. AstraZeneca had a return on equity of 30.73% and a net margin of 12.61%. The firm's quarterly revenue was down 4.2% on a year-over-year basis. During the same period in the prior year, the business earned $0.99 earnings per share. View AstraZeneca's Earnings History.

AstraZeneca is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for AstraZeneca.

AstraZeneca issued an update on its FY18 earnings guidance on Friday, May, 18th. The company provided EPS guidance of $3.30-3.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.46.

19 equities research analysts have issued 1-year price targets for AstraZeneca's stock. Their predictions range from $35.00 to $42.00. On average, they expect AstraZeneca's stock price to reach $38.2833 in the next year. View Analyst Ratings for AstraZeneca.

AstraZeneca saw a increase in short interest in the month of May. As of May 31st, there was short interest totalling 12,406,265 shares, an increase of 37.3% from the May 15th total of 9,036,979 shares. Based on an average trading volume of 5,020,054 shares, the days-to-cover ratio is presently 2.5 days. Approximately 0.5% of the company's stock are sold short.

Some companies that are related to AstraZeneca include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Bayer (BAYRY), GlaxoSmithKline (GSK), Sanofi (SNY), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Allergan (AGN), Celgene (CELG) and Shire (SHPG).

Press coverage about AZN stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. AstraZeneca earned a media sentiment score of 0.13 on Accern's scale. They also gave news articles about the company an impact score of 45.47 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

AstraZeneca's stock is owned by many different of retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (0.50%), Epoch Investment Partners Inc. (0.34%), BlackRock Inc. (0.26%), Schafer Cullen Capital Management Inc. (0.18%), Federated Investors Inc. PA (0.17%) and Wells Fargo & Company MN (0.15%). View Institutional Ownership Trends for AstraZeneca.

AZN stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Sei Investments Co., Wells Fargo & Company MN, Envestnet Asset Management Inc., Epoch Investment Partners Inc., Russell Investments Group Ltd., Farallon Capital Management LLC and Guggenheim Capital LLC. View Insider Buying and Selling for AstraZeneca.

AZN stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Crawford Investment Counsel Inc., Senzar Asset Management LLC, Millennium Management LLC, Fisher Asset Management LLC, Global Financial Private Capital LLC, Thornburg Investment Management Inc. and PointState Capital LP. View Insider Buying and Selling for AstraZeneca.

Shares of AZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of AZN stock can currently be purchased for approximately $35.94.

AstraZeneca has a market capitalization of $92.22 billion and generates $22.47 billion in revenue each year. The company earns $3.00 billion in net income (profit) each year or $4.28 on an earnings per share basis. AstraZeneca employs 61,100 workers across the globe.

AstraZeneca's mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The company can be reached via phone at 44-20-3749-5000 or via email at [email protected]